SPONTAN Now in 600+ Pharmacies: What This Means for LTR Pharma’s Growth
LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.
- SPONTAN now available at over 600 TerryWhite Chemmart pharmacies across Australia
- New TGA-compliant barcoded packaging supports pharmacy integration and telehealth
- Dispensing under Special Access and Authorised Prescriber Schemes
- Real-world data collection enabled to inform regulatory and commercial plans
- Pharmacist education underway to support product rollout
Expanding Patient Access
LTR Pharma Limited (ASX:LTP) has taken a pivotal step in broadening access to its intranasal erectile dysfunction treatment, SPONTAN, by making it available through TerryWhite Chemmart’s national pharmacy network. This rollout covers more than 600 pharmacy locations across Australia, significantly enhancing patient convenience and availability.
The move follows LTR Pharma’s January 2025 distribution agreement with Symbion Pty Ltd, a subsidiary of the EBOS Group, which operates TerryWhite Chemmart. This partnership leverages one of the country’s largest pharmacy footprints, spanning metropolitan and regional areas alike.
Innovative Packaging and Telehealth Integration
To support this expanded access, LTR Pharma has developed new commercial packaging for SPONTAN that complies with Therapeutic Goods Administration (TGA) regulations. The packaging features barcodes designed to integrate with pharmacy inventory systems and future telehealth platforms, streamlining the prescription and dispensing process.
This innovation not only facilitates efficient pharmacy operations but also opens pathways for patients to consult healthcare professionals remotely, aligning with evolving healthcare delivery models.
Regulatory Framework and Pharmacist Support
SPONTAN is dispensed under the TGA’s Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS), ensuring that patients receive the treatment through authorised healthcare professionals. LTR Pharma has also invested in pharmacist education, preparing clinical insights and dispensing guidance to be shared at an upcoming TerryWhite Chemmart Masterclass in June 2025.
This educational initiative aims to equip pharmacists with the knowledge required to support patients effectively and ensure compliance with regulatory standards.
Real-World Data and Future Prospects
The expanded pharmacy rollout enables LTR Pharma to collect valuable real-world data on SPONTAN’s usage, patient experiences, and prescribing patterns. This data is critical for the company’s regulatory strategy as it prepares for a full commercial launch in Australia and anticipates the 2026 US launch of its related product, ROXUS.
Executive Chairman Lee Rodne highlighted the significance of this milestone, emphasizing the enhanced patient access and the streamlined pathway from healthcare professional to pharmacy dispensing.
Bottom Line?
As SPONTAN gains broader pharmacy presence, LTR Pharma positions itself for regulatory success and commercial growth ahead.
Questions in the middle?
- How quickly will patient uptake grow across the expanded pharmacy network?
- What insights will real-world data reveal about SPONTAN’s market potential and patient outcomes?
- When can investors expect regulatory decisions on SPONTAN’s full commercial approval in Australia?
